Keywords: Merck & Co, Samsung Bioepis, Biogen Idec, Biosimilars development and production, South Korea

Merck & Co in biosimilars deal with Samsung Bioepis

Article | 21 February 2013

Print This

US pharma giant Merck & Co (NYSE: MRK) has entered into an agreement with South Korea-based Samsung Bioepis to develop ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in